4DMedical Reports Strong FY2025 Growth and Expanding Global Footprint.

4DMedical Limited (ASX: 4DX) has delivered a strong FY2025 performance, marked by significant revenue growth, product advancements, and global expansion. Operating revenue rose 56% to AU$5.9 million, driven largely by Software-as-a-Service income, which nearly doubled year-on-year. The company implemented a cost-reduction program in Q3, generating AU$6.5 million in annualised savings while maintaining focus on revenue growth. An AU$10 million strategic investment from Pro Medicus further strengthened its financial position.

Key milestones included the FDA 510(k) submission for its innovative CT: VQ lung imaging tool, which offers superior accessibility and resolution compared to traditional ventilation-perfusion scans. Commercial momentum accelerated with new U.S. contracts at UChicago Medicine and UCSD Health, alongside renewals at leading institutions such as Stanford and Cleveland Clinic. In Australia, partnerships expanded with Integral Diagnostics, QScan, and PRC. By FY2025, 4DMedical was delivering SaaS products at 388 sites globally, producing 194,789 scans, up 105% year-on-year.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com